安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Home - Cingulate Inc
Cingulate is a clinical stage biopharmaceutical company focused on the development of innovative new product candidates for the treatments of Attention Deficit Hyperactivity Disorder (ADHD) and anxiety associated disorders
- Board of Directors - Cingulate Inc
He serves as a board of director for the following companies: VM Pharma LLC, VM Therapeutics LLC, VM Oncology LLC, Likarda LLC, Altos Therapeutic, Alzeca, Nuance, Perseus and Cingulate Therapeutics LLC Mr Werth has formed LLCs to develop commercial projects using specific technologies which reflect his strong entrepreneurial interests and
- FDA Accepts Cingulate’s New Drug Application for CTx-1301 in Attention . . .
Cingulate’s lead candidate, CTx-1301, is in late-stage development for ADHD, with additional candidates in anxiety and other neuropsychiatric indications Cingulate is headquartered in Kansas City, Kansas
- Cingulate Inc. Reports Third Quarter 2025 Financial Results and . . .
“Cingulate has made meaningful progress this quarter toward key value-creating milestones,” said Jay Roberts, Executive Chairman of Cingulate
- CTx-1301 - Cingulate Inc
CTx-1301 utilizes Cingulate’s innovative Precision Timed Release™ (PTR™) drug delivery platform technology to create a breakthrough multi-core formulation of dexmethylphenidate, a compound approved by the FDA for the treatment of ADHD
- Cingulate Announces Adjournment of Special Meeting - Cingulate Inc
With an initial focus on the treatment of attention deficit hyperactivity disorder (ADHD), Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders
- SEC Filings - Cingulate Inc
Stonegate Capital Partners Initiates Coverage on Cingulate Inc (NASDAQ: CING) Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
- Once-daily precision. Entire day control. - cingulate. com
Leader in Drug Development: Co-founded Cingulate Therapeutics; contributed to FDA approval of 15+ CNS drugs Academic Professional Recognition: Clinical Associate Professor at Baylor; published 20+ articles; Senior Board Examiner for ABPN
|
|
|